Compare IDYA & HURN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDYA | HURN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 2.9B |
| IPO Year | 2019 | 2004 |
| Metric | IDYA | HURN |
|---|---|---|
| Price | $31.03 | $168.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 5 |
| Target Price | $51.54 | ★ $202.00 |
| AVG Volume (30 Days) | ★ 986.4K | 446.2K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ 4.96 |
| Revenue | $218,710,000.00 | ★ $1,699,143,000.00 |
| Revenue This Year | N/A | $12.58 |
| Revenue Next Year | $216.42 | $8.98 |
| P/E Ratio | ★ N/A | $34.88 |
| Revenue Growth | ★ 3024.43 | 11.65 |
| 52 Week Low | $26.81 | $84.88 |
| 52 Week High | $42.68 | $203.37 |
| Indicator | IDYA | HURN |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 40.91 |
| Support Level | $29.74 | $119.02 |
| Resistance Level | $35.44 | $171.46 |
| Average True Range (ATR) | 1.53 | 9.08 |
| MACD | -0.21 | -3.19 |
| Stochastic Oscillator | 4.75 | 15.08 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.